top of page

Our Mission

 improve immunological safety and efficacy of vaccines, drugs, and immune therapies by automating precise analysis of T-cell responses

Unmatched Efficiency for Immune Therapy Developers

100XBIO is a pioneering biotech hardware startup based in Boston, Massachusetts, founded in 2023.

​

Our technology significantly boosts the efficiency of clinical trials for therapeutic cancer vaccines by allowing the enrollment of more participants and rapidly validating numerous neoantigen targets for personalized cancer treatments.

 

Our solutions are designed for researchers and scientists in the biotech industry who are focused on developing cutting-edge cancer therapies and require precise, reliable data to drive their innovations forward.

Our Team

Led by a team of seasoned experts, including our CEO and founder Sergei Pustylnikov, we provide valuable insights and analyses that drive the biotech industry forward.

Screenshot_2024-08-01_at_3.29_edited.png

Sergei Pustylnikov, Ph.D. 

Founder & CEO

1680819033747_edited.png

ML Engineer

1718833907945-removebg-preview.png

Srusti Bheem Sain

R&D Engineer

Core Team

Advisors

Screenshot_2024-08-01_at_3.34.10_PM-removebg-preview.png

Askar K., PhD.

Business Advisor, 2x CEO,

VC management

1700936219725__1_-removebg-preview.png

Sofya Leyn, Ph.D

Co-founder, Data analysis, Sequencing

Screenshot_2024-08-01_at_3.43_edited.png

Andrei Afanasiev

VC partner, 2x CEO, VC Funding Advising

Screenshot_2024-08-01_at_3.46_edited.png

PhD, Biotech executive, Product Development

Get in Touch

100XBIO @C2I Accelerator

299 Washington St

Woburn, MA 01801 

bottom of page